Loading clinical trials...
Loading clinical trials...
A Phase II Study of WX-0593 Combined With Concurrent Chemoradiotherapy in the Treatment of Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of ALK or ROS1
Conditions
Interventions
WX-0593 Tablets
chemotherapy
+1 more
Locations
1
China
Shandong Cancer Hospital and Institute
Jinan, Shandong, China
Start Date
April 30, 2022
Primary Completion Date
April 30, 2026
Completion Date
May 30, 2026
Last Updated
April 28, 2022
NCT06476808
NCT07361497
NCT07510724
NCT06305754
NCT07130786
NCT06895031
Lead Sponsor
Jinming Yu
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions